The Paris-based life sciences VC company’s new fund Sofinnova MD Start IV represents a substantial increase from its predecessor,Sofinnova MD Start III, which closed at €63 million ($71 million). This growth trajectory underscores the expanding appetite for early-stage medtech innovation.
